IMPORTANT SAFETY INFORMATIONPRESCRIBING INFORMATION

FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated.

Monitoring information for renal function1

  • For patients with severe renal impairment (eGFR 15 to <30mL/min/1.73 m2), the recommended dose of FOLOTYN is 15 mg/m2
  • For patients with mild to moderate renal impairment, dose reduction is not necessary
  • Patients with moderate to severe renal function impairment may be at greater risk for increased exposure and toxicity
  • Monitor patients for renal function and systemic toxicity and adjust dosing accordingly
  • Avoid FOLOTYN use in patients with end stage renal disease including those undergoing dialysis unless the potential benefit justifies the potential risk

Reference:

  • Folotyn [package insert]. Westminster, CO: Allos Therapeutics, Inc.